(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.

Fig. 7. Inhibition of Ins(1,4,5)P3 and calcium but not PKC inhibits early changes in cell morphology. (A) BE cells plated on Matrigel and treated for 8 hours with either 2-APB (40 µM) an Ins(1,4,5)P3 receptor antagonist, BAPTA-AM (20 µM), an intracellular calcium-chelating agent, thapsigargin (THAPS; 100 nM) an inhibitor of the sarcoplasmic endoplasmic reticulum calcium ATPase or the PKC inhibitor compounds R0-31-8220 (3 µM) or GF109203X (3 µM) and its structurally related control bisindolylmaleimide V (BiV) (3 µM). Cell elongation was analysed by microscopy with representative images shown and average percentage cell elongation, analysed from 20 independent cell images reported with standard deviations; control 161.2±17.8%, APB-2 7.7±6.4%, BAPTA-AM 1.8±6.5%, thapsigargin 3.2±4.3%, RO-31-8220 45.0±17.9%, GFX109203X 41.0±21.3%, BisV 154±16.7%. (B) HUVECs were plated on Matrigel and treated as for part A. Cell elongation and networking was analysed by fluorescent microscopy. (C) Serum-starved cells treated as for part A were plated onto Matrigel-coated Transwell chambers and invasion through the filter and into the matrix, towards serum (10%) was analysed by microscopy after 48 hours with the average percentage (number) of invading cells compared with control (untreated, 100%) sample from five experiments displayed with standard deviations. 1, control; 2, 2-APB; 3, BAPTA-AM; 4, R0-31-8220; 5, GFX109203X; 6, BiV.